Literature DB >> 15707019

[Myelotoxicity of high-molecular-weight poly(ethylene oxide)].

G V Karpova, E V Abramova, T Iu Lamzina, E A Timina, T V Vetoshkina.   

Abstract

The effects of administration of the parent substance of high-molecular-weight poly(ethylene oxide) (HMWPEO) with a molecular mass of 3-6 x 10(6) D and the related drug polyetox (representing a water-soluble lyophilized form of HMWPEO suitable for intravenous injection) on the characteristics of peripheral blood and bone marrow were studied in rats. HMWPEO was injected intravenously and intraperitoneally in a single toxic dose. Polyetox was injected intraperitoneally in a therapeutic dose and in 3- and 10-fold doses over a period of 30 days. Single i.v. and i.p. injections of HMWPEO in the maximum tolerable dose leads to a dose-dependent reversible hemolytic anemia of medium degree, neutrophilic leukocytosis, lymphopenia, and thrombocytopenia. The chronic i.p. adminstration of polyetox in a 10-fold therapeutic dose caused red blood cell lysis and led to the development of reversible regenerative anemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15707019

Source DB:  PubMed          Journal:  Eksp Klin Farmakol        ISSN: 0869-2092


  6 in total

1.  A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER.

Authors:  Ryan Hunt; Ayla Yalamanoglu; James Tumlin; Tal Schiller; Jin Hyen Baek; Andrew Wu; Agnes B Fogo; Haichun Yang; Edward Wong; Peter Miller; Paul W Buehler; Chava Kimchi-Sarfaty
Journal:  Blood       Date:  2016-11-18       Impact factor: 22.113

2.  Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone.

Authors:  Melissa Nataatmadja; Dakshinamurthy Divi
Journal:  Clin Kidney J       Date:  2016-05-30

3.  Opana ER (Oxymorphone)-Induced Thrombotic Microangiopathy: An Atypical Presentation in a Patient With Hepatitis C.

Authors:  Hassan Mehmood; Muzammil Khan; Asghar Marwat; Medha Joshi; Varun Malhotra
Journal:  J Investig Med High Impact Case Rep       Date:  2018-01-31

4.  Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ER.

Authors:  Kamia Thakur; Vaibhav Agrawal; Ashley Kass; Lauren M Dimarino; R Patrick Dorion; Joseph Vadakara
Journal:  Case Rep Hematol       Date:  2017-05-18

5.  Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-01-11       Impact factor: 17.586

6.  Bilateral exudative retinal detachments due to thrombotic microangiopathy associated with intravenous abuse of Opana ER.

Authors:  Fazila Aseem; Brian G Zamora; Levi Kauffman; Peter J Miller; Vishak J John
Journal:  Am J Ophthalmol Case Rep       Date:  2018-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.